1403357-80-1
Chemical Structure
ACT001 hydrochloride
Synonym(s): Dimethylaminomicheliolide hydrochloride; DMAMCL hydrochloride
- CAS No.: 1403357-80-1
- Formula:C17H28ClNO3
- Molecular Weight:329.86
IUPAC Name: (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3a,4,5,7,8,9,9a,9b-octahydroazuleno[4,5-b]furan-2(3H)-one hydrochloride
InChIKey: ZKHJWBSQJWCFMA-GMFVQMBMSA-N
SMILES: C[C@@]1([C@]2([H])[C@]3([H])[C@](CCC(C)=C2CC1)([H])[C@@H](C(O3)=O)CN(C)C)O.Cl
Biological Activity: ACT001 (Dimethylaminomicheliolide; DMAMCL) hydrochloride is an orally active, blood-brain barrier-permeable anti-inflammatory and anti-tumor agent. ACT001 hydrochloride exerts microglia-mediated neuroanti-inflammatory effects by inhibiting the AKT/NF-κB/NLRP3 axis and suppressing apoptosis (apoptosis). ACT001 hydrochloride inhibits tumor proliferation by upregulating NKTR and inhibiting AKT. ACT001 hydrochloride alleviates metabolic-associated fatty liver disease by regulating gut microbiota and inhibiting ileal FXR. ACT001 hydrochloride inhibits pyroptosis (pyroptosis) and pro-inflammatory cytokine release by activating PPAR-γ and inhibiting NF-κB/NLRP3[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ACT001 hydrochloride | ACT001 (Dimethylaminomicheliolide; DMAMCL) hydrochloride is an orally active, blood-brain barrier-permeable anti-inflammatory and anti-tumor agent. ACT001 hydrochloride exerts microglia-mediated neuroanti-inflammatory effects by inhibiting the AKT/NF-κB/NLRP3 axis and suppressing apoptosis (apoptosis). ACT001 hydrochloride inhibits tumor proliferation by upregulating NKTR and inhibiting AKT. ACT001 hydrochloride alleviates metabolic-associated fatty liver disease by regulating gut microbiota and inhibiting ileal FXR. ACT001 hydrochloride inhibits pyroptosis (pyroptosis) and pro-inflammatory cytokine release by activating PPAR-γ and inhibiting NF-κB/NLRP3. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fu Q, et al. ACT001 alleviates inflammation and pyroptosis through the PPAR-γ/NF-κB signaling pathway in LPS-induced alveolar macrophages. Genes & genomics. 2024 Mar;46(3):323-332. [Content Brief]
- [2]. Zhao M, et al. ACT001 inhibits the proliferation of non-small cell lung cancer cells by upregulating NKTR expression. Thoracic cancer. 2022 Jun;13(12):1772-1782. [Content Brief]
- [3]. Cai L, et al. ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway. Cell communication and signaling : CCS. 2022 Apr 23;20(1):56. [Content Brief]
- [4]. Niu B, et al. ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice. Annals of medicine. 2025 Dec;57(1):2580773. [Content Brief]
